We are live on ! Find out more
XBIT icon

XBiotech

39 hedge funds and large institutions have $20.7M invested in XBiotech in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more capital invested

Capital invested by funds: $8.61M → $20.7M (+$12.1M)

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

3.41% more ownership

Funds ownership: 8.03%11.44% (+3.4%)

3% more funds holding

Funds holding: 3839 (+1)

26% less call options, than puts

Call options by funds: $23K | Put options by funds: $31K

Holders
39
Holders Change
+1
Holders Change %
+2.63%
% of All Funds
0.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
12
Reduced
10
Closed
6
Calls
$23K
Puts
$31K
Net Calls
-$8K
Net Calls Change
+$29K
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
1
Millennium Management
New York
$5.7M +$4.12M +914,107 +2,002%
Vanguard Group
2
Vanguard Group
Pennsylvania
$5.18M +$81.1K +17,974 +2%
BlackRock
3
BlackRock
New York
$1.72M +$125K +27,651 +11%
CS
4
Credit Suisse
Switzerland
$1.46M
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.03M +$81.7K +18,098 +12%
BCM
6
Bridgeway Capital Management
Texas
$752K +$55.7K +12,336 +11%
Morgan Stanley
7
Morgan Stanley
New York
$498K -$15.4K -3,411 -4%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$442K -$3.66K -812 -1%
Connor, Clark & Lunn Investment Management (CC&L)
9
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$382K +$28.8K +6,378 +11%
State Street
10
State Street
Massachusetts
$336K -$3.47K -769 -1%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$331K
Man Group
12
Man Group
United Kingdom
$305K +$231K +51,292 New
EST
13
EA Series Trust
Pennsylvania
$296K +$225K +49,776 New
EF
14
Empowered Funds
Pennsylvania
$296K +$225K +49,776 New
Northern Trust
15
Northern Trust
Illinois
$285K +$185 +41 +0.1%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$270K -$11.3K -2,500 -5%
Two Sigma Investments
17
Two Sigma Investments
New York
$268K -$44.7K -9,897 -18%
Renaissance Technologies
18
Renaissance Technologies
New York
$168K -$109K -24,160 -46%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$119K -$1.8K -400 -2%
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$105K
Citadel Advisors
21
Citadel Advisors
Florida
$98.6K -$17K -3,775 -19%
Bank of America
22
Bank of America
North Carolina
$81.7K -$1.6K -355 -3%
TNB
23
Thomasville National Bank
Georgia
$79.3K
Jane Street
24
Jane Street
New York
$78.5K +$59.6K +13,207 New
SF
25
Synovus Financial
Georgia
$70.1K

XBIT Hedge Fund Activity: Q2 2023 in Review

39 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2023, worth a combined $20.7M — up 140% from $8.61M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new XBIT positions and 6 closed out — a net gain of 1 holder — while 12 added to existing stakes and 10 trimmed.

The largest buyer was Millennium Management, adding an estimated $4.12M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $132K sold.

  • 39 institutional investors held XBiotech (XBIT) as of Q2 2023, up from 38 in Q1 2023.
  • Funds reported $20.7M of XBiotech stock for Q2 2023, up 140% quarter-over-quarter.
  • 7 funds opened new XBiotech positions in Q2 2023 and 6 closed out, a net change of +1 holder.
  • The largest XBiotech buyer in Q2 2023 was Millennium Management, an estimated $4.12M added.
  • The largest XBiotech seller in Q2 2023 was Susquehanna International Group, an estimated $132K sold.

Based on aggregated 13F filings for Q2 2023.